HER2+ Breast Cancer | Specialty

Adjuvant T-DM1/Pertuzumab Combo Misses iDFS End Point in High-Risk HER2-Positive Breast Cancer

July 16th 2020

Anthracycline-based chemotherapy followed by ado-trastuzumab emtansine plus pertuzumab did not show statistically significant or clinically meaningful improvement in invasive disease-free survival in patients with high-risk HER2-positive early breast cancer, missing the primary end point of the phase 3 KAITLIN trial.

Han Highlights the Need for Personalized Treatment in HER2+ Early-Stage Breast Cancer

July 15th 2020

Heather Han, MD, discusses ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.

Dr. Czerniecki on Treatment Options for Patients With HER2+ Brain Metastases

July 15th 2020

Brian Czerniecki, MD, PhD, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases.

Trastuzumab Deruxtecan Shows Broad Benefit in Metastatic HER2+ Breast Cancer

July 13th 2020

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Dr. Lin on Developing Systemic Therapies for Patients with Brain Metastases in HER2+ Breast Cancer

July 9th 2020

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Systemic Therapies Improve Breast Cancer With Brain Metastases Management

July 7th 2020

Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival for these patients, and a number of agents on the horizon.

Expert Highlights Unmet Need for Patients With Metastatic HER2+ Breast Cancer and Brain Metastases

July 6th 2020

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

FDA Approves Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer

June 29th 2020

The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase, administered via subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.

Tucatinib Produces Potent Preclinical Antitumor Activity, CNS Penetrance in HER2+ Breast Cancer

June 23rd 2020

The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.

Alpha-TEA and Concurrent Trastuzumab Under Exploration in Refractory HER2+ Breast Cancer

June 17th 2020

William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 10th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases

June 5th 2020

Collectively, there are more options than ever in the space of HER2-positive breast cancer brain metastases, a significant advance for our hundreds and thousands of patients facing this challenging disease.

Sacituzumab Govitecan Becomes First ADC Approved for TNBC

June 3rd 2020

Aditya Bardia, MD, MPH, discusses how the antibody-drug conjugate sacituzumab govitecan-hziy can address the unmet need in metastatic triple-negative breast cancer and the toxicities seen with the therapy.

Dr. Gwin on the Safety of α-TEA Plus Trastuzumab in Recurrent HER2+ Breast Cancer

June 3rd 2020

William R. Gwin III, MD, discusses the safety profile of alpha-tocopheryloxyacetic acid in combination with trastuzumab in recurrent HER2-positive metastatic breast cancer.

Dr. Lin on Updated Findings of HER2CLIMB Study in HER2+ Breast Cancer Brain Mets

May 30th 2020

Nancy U. Lin, MD, discusses updated findings from the phase 2 HER2CLIMB study in patients with HER2-positive metastatic breast cancer with brain metastases.

FDA Waives ODAC Review of Margetuximab in HER2+ Breast Cancer

May 28th 2020

The FDA’s Oncologic Drugs Advisory Committee will no longer be meeting to review a Biologics License Application for margetuximab for the treatment of patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets

May 24th 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline.

Dr. Park on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 23rd 2020

Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.

Relapsed/Refractory HER2+ mBC: Future Treatment Landscape

May 18th 2020

HER2CLIMB: Sequencing in Metastatic Breast Cancer

May 18th 2020